Their software integrates diverse data points from clinical and drug development fields to predict patient responses to therapies, allowing pharmaceutical and biotech companies to optimize trial design and increase success rates. The last investment of $2.00M in Series A was secured on 08 January 2024 from Accenture Ventures. This backing from a established firm like Accenture Ventures is a strong validation of the potential of QuantHealth's technology in transforming the pharmaceutical and AI industries.
QuantHealth
Accelerating drug development with AI-driven patient-centric medication simulations to enhance trial design and boost success rates.
Founded 2020
11-50 employees
Series A
Total: $17.00M
AI, Pharmaceutical
General Information
Company Name
QuantHealth
Founded Year
2020
Founders / Decision Makers
Employees
11-50
Industries
AI, Pharmaceutical
Funding Stage
Series A
BounceWatch is an independent company data service, not affiliated with QuantHealth. To contact QuantHealth, visit quanthealth.ai.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does QuantHealth compare?
A PDF of QuantHealth and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting QuantHealth soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
Discover More
About QuantHealth
Business keywords: Drug Simulation, Bioinformatics, RWD/RWE, Computational Biology, Trial Simulation, Patient Centric Drug Development, In-Silico Medicine, Clinical Data Science, Health Informatics, Oncology, Auto-Immune, Respiratory, HemOnc, Drug R&D, Patient Outcomes
Funding Rounds & Investors (3)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Series A | $2.00M | 1 |
Accenture Ventures
|
08 Jan 2024 |
| Series A | $15.00M | 7 |
|
30 Aug 2023 |
| Seed Round | Undisclosed | 1 |
|
10 Jun 2022 |
QuantHealth Alternatives & Competitors
View All Alternatives
QuantHealth vs
MNM Bioscience
United States
From tumor genomes to AI-driven drug discovery
Seed
2 employees
AI, Biotechnology
QuantHealth vs
QuantHealth vs
Ancora.ai
Switzerland
Ancora.ai is a patient-first, digital clinical trial navigation tool connecting cancer patients to c...
Grant
9 employees
AI, Big Data
FAQ About QuantHealth
Accelerating drug development with AI-driven patient-centric medication simulations to enhance trial design and boost success rates.
QuantHealth was founded in 2020.
QuantHealth operates in AI and Pharmaceutical. Its work centres on Drug Simulation, Bioinformatics, RWD/RWE and Computational Biology.
QuantHealth has approximately 11-50 employees.
QuantHealth has completed 3 funding rounds, raising a total of $17.00M. The latest funding stage is Series A.
Top alternatives and competitors to QuantHealth include MNM Bioscience, ConcertAI, Ancora.ai, Lantern Pharma Inc. (Nasdaq: LTRN), OWKIN. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
QuantHealth and MNM Bioscience are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.
Source: BounceWatch company record for QuantHealth, https://bouncewatch.com/company/quanthealth, updated 20 December 2024. When citing, please name BounceWatch and link this page.
